NCT02883595View on ClinicalTrials.gov

Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions
Sepsis
Interventions
DRUG

thymosin alpha 1

Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.

OTHER

Placebo

Subcutaneous injections of placebo (saline) twice per day for seven days

Trial Locations (1)

510080

Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02883595 - Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis | Biotech Hunter | Biotech Hunter